



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. AM101193)

<i>In re</i> Patent Application of:)	Appln. No.: 10/648,667
)	Confirmation No.: 3920
CHENGJIN M. HUANG)	Group Art Unit: 1648
)	Examiner: Emily M. Le
Filed: August 26, 2003)	
)	
For: MONOCLONAL ANTIBODY SPECIFIC FOR)	
AN EPITOPE OF INACTIVATED FELINE IMMUNO-)	
DEFICIENCY-ENCODED GLYCOPROTEIN)	

AMENDMENT AFTER FINAL REJECTION
PURSUANT TO 37 C.F.R. § 1.116

Dear Sir:

Responsive to the Official action mailed November 29, 2005, please amend the above-referenced patent application using the following instructions and consider the remarks in a favorable light:

REMARKS

Reconsideration of this application, in view of the amendment, is respectfully requested. In accord with 37 C.F.R. § 1.121, the proposed amendment to the claims and a complete listing of all claims in the application begin on a separate sheet to facilitate separate indexing and electronic scanning of the amendment for placement in an e-file wrapper. The amendment adds no new matter into the application. For the convenience of the Office staff, the amendment is placed in the below Appendix and incorporated herein by reference thereto.

Currently, Claims 1-22 are pending. Product Claims 1-10 and 19-22 are under examination. While method Claims 11-18 have been withdrawn from consideration, they are retained in this response to provide the Examiner the opportunity to rejoin these method claims in the event that the product claims are allowed. To make rejoinder possible, the claims drawn to the non-elected invention are being amended to require all the limitations of the elected invention recited in product Claim 1 as amended.

The Examiner sustains the rejection of Claims 1-10 and 19-21 under 35 U.S.C. § 112, second paragraph, asserting that the claims are indefinite for reasons provided on pages 2 and 3 of the Office action. Although Applicant respectfully disagrees with the merits of the rejection,

Page 1 of 7